DC and FunPlus Collaborate to Bring The Joker to “State of Survival” in a Thrilling New Story Campaign
15.11.2021 21:56:00 EET | Business Wire | Press release
FunPlus, a leading mobile game developer and publisher, as well as its KingsGroup studio today announced that The Joker will arrive as a new playable character in the free-to-play strategy game State of Survival, available on both iOS and Android. Licensed by Warner Bros. Interactive Entertainment on behalf of DC, all players who complete the story campaign will have a limited window to permanently unlock The Joker.
Later this fall, horror will grip the Settlement as a terrifying breed of laughing zombies begin to attack settlers. When a stranger in a purple suit claims to have survived an attack and volunteers to help, players will embark on a story campaign brimming with intrigue, mystery, and perhaps even betrayal! Check out the teaser trailer here and get ready for the most devious crossover of the year!
“Welcoming a notorious Super-Villain like The Joker to State of Survival and working with an entertainment powerhouse like DC is a huge honor. We are excited to deliver this blockbuster collaboration to our existing players and look forward to welcoming DC fans to check out our post-apocalyptic world in the game,” said Chris Petrovic, Chief Business Officer, FunPlus. “State of Survival has had a phenomenal 2021, and we have no plans to slow down any time soon!”
FunPlus recently announced that State of Survival has passed 100 million downloads, just in time to celebrate the game’s second anniversary.
For more information on DC, visit dccomics.com. For more information on FunPlus, visit http://www.funplus.com. For more information on State of Survival, visit https://funplus.com/games/state-of-survival/. Find a link to assets here and the teaser trailer here.
About FunPlus
Founded in 2010, FunPlus is a world-class, independent game developer and publisher headquartered in Switzerland and with operations in China, Japan, Singapore, Spain, Sweden, Russia, and the United States.
As an organization that fosters the best creative and diverse talent in the world and employs nearly 2,000 people, the company has developed and published games that have ranked in the #1 spot in nearly 70 countries, including State of Survival, King of Avalon and Guns of Glory.
FunPlus studios include KingsGroup, Puzala, Seven Games and Imagendary Studios, each with a focus on developing a unique brand of innovative games for global audiences.
FunPlus is the founder of FPX (FunPlus Phoenix), one of the world's most successful esports organizations, and the 2019 League of Legends World Champions.
About Warner Bros. Interactive Entertainment
Warner Bros. Interactive Entertainment is a premier worldwide publisher, developer, licensor and distributor of entertainment content for the interactive space across all platforms, including console, handheld, mobile and PC-based gaming for both internal and third-party game titles. Additional information can be found at www.wbgames.com.
About DC
DC is one of the largest English-language publishers of comics and graphic novels in the world and home to some of the most iconic and recognizable characters ever created. As a creative unit of WarnerMedia, DC is charged with strategically integrating its stories and characters across film, television, consumer products, home entertainment, interactive games, and the DC UNIVERSE INFINITE digital subscription service and community engagement portal. For more information visit dccomics.com and dcuniverseinfinite.com.
™ & © DC Comics. ™ & © Warner Bros. Entertainment Inc. (s21)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211115006157/en/
Contact information
42West/BHI for FunPlus
Jamie King
jamie_king@bhimpact.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom